The latest price target for Janux Therapeutics (NASDAQ:JANX) was reported by Cantor Fitzgerald on September 16, 2024. The analyst firm set a price target for $100.00 expecting JANX to rise to within 12 months (a possible 99.20% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Janux Therapeutics (NASDAQ:JANX) was provided by Cantor Fitzgerald, and Janux Therapeutics reiterated their overweight rating.

There is no last upgrade for Janux Therapeutics

There is no last downgrade for Janux Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Janux Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Janux Therapeutics was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest Janux Therapeutics (JANX) rating was a reiterated with a price target of $100.00 to $100.00. The current price Janux Therapeutics (JANX) is trading at is $50.20, which is out of the analyst’s predicted range.